Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Albert Galdi

Neuromusculoskeletal Medicine & OMM Wheaton, MD Medical Doctor

NPI 1760480917 CMS profile 307275

2730 University Blvd W Ste 310, Arthritis & Rheuma Assocs, Wheaton, MD 20902

Open in the dashboard

General payments

$15,158

178 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Albert Galdi of Wheaton, MD is reported in the CMS Open Payments database as having received $15,158 across 178 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Neuromusculoskeletal Medicine & OMM profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $55 3
2021 General $24 1
2020 General $13,458 91
2019 General $1,621 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Albert Galdi
  • Neuromusculoskeletal Medicine & OMM median
  • Middle half of Neuromusculoskeletal Medicine & OMM
  • National median

In program year 2025, general payments to Albert Galdi were reported at $0. Among 217 Neuromusculoskeletal Medicine & OMM profiles paid that year, the median was $119 and the middle half received between $36 and $380.

Show as a table
Year Albert Galdi Neuromusculoskeletal Medicine & OMM median Middle half National median
2019 $1,621 $92 $27–$283 $163
2020 $13,458 $85 $20–$411 $114
2021 $24 $120 $32–$548 $132
2022 $55 $96 $32–$518 $149
2023 $0 $92 $33–$328 $160
2024 $0 $122 $35–$378 $164
2025 $0 $119 $36–$380 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Allergan Inc. $12,746 49 payments
  2. Teva Pharmaceuticals USA, Inc. $733 43 payments
  3. Novartis Pharmaceuticals Corporation $458 24 payments
  4. Biogen, Inc. $187 3 payments
  5. EMD Serono, Inc. $171 12 payments
  6. Supernus Pharmaceuticals, Inc. $122 6 payments
  7. Lundbeck LLC $118 7 payments
  8. Sunovion Pharmaceuticals Inc. $99 6 payments
  9. Genentech USA, Inc. $92 5 payments
  10. Alexion Pharmaceuticals, Inc. $72 3 payments
  11. Other $360 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $11,125 9 payments
  2. Food and Beverage $3,092 161 payments
  3. Travel and Lodging $777 5 payments
  4. Consulting Fee $150 1 payment
  5. Education $13 2 payments
Products named General payments · program years 2019–2022
  1. UBRELVY $12,594 36 payments
  2. Ajovy Central Nervous System $431 23 payments
  3. MAYZENT $387 19 payments
  4. AJOVY Central Nervous System $207 14 payments
  5. TYSABRI $150 1 payment
  6. GILENYA $138 8 payments
  7. BOTOX $129 11 payments
  8. Mavenclad $104 8 payments
  9. APTIOM $99 6 payments
  10. NORTHERA $97 6 payments
  11. Other $1,039 57 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$26,658

Medicare's payments for the services billed

Medicare patients

99

Average age 74

Services billed

266

72 women, 27 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 71%
Osteoporosis 34%
Diabetes 24%
Ischemic heart disease 24%
Depression 16%
Atrial fibrillation 12%
Chronic kidney disease 11%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

178 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neuromusculoskeletal Medicine & OMM in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record